MBX Biosciences Inc
Pharmaceuticals
MBX Biosciences Inc (MBX) Stock News
The latest MBX headlines and market coverage — 2 recent stories, updated throughout the day.
- GlobeNewswire Inc.·
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
MBX Biosciences announced positive one-year data from its open-label extension study of canvuparatide, a once-weekly PTH replacement therapy for chronic hypoparathyroidism. The drug maintained a 57% responder rate at one year with a 90% retention rate, demonstrated sustained benefits in calcium homeostasis, kidney function, and bone metabolism, and showed no new safety signals. The company remains on track to initiate Phase 3 pivotal trials in Q3 2026.
- GlobeNewswire Inc.·
MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Supporting Potential for Once-Monthly Dosing
MBX Biosciences announced preliminary Phase 1 data for MBX 4291, a GLP-1/GIP co-agonist prodrug showing 7% mean weight loss at 8 weeks with good tolerability and potential for once-monthly dosing. The company also nominated MBX 5765, a novel four-agonist candidate for obesity, and achieved proof of concept for imapextide in post-bariatric hypoglycemia, though will not pursue further Phase 2b development of the latter to prioritize resources.